Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM2BP4
The NM_007294.4(BRCA1):āc.488G>Cā(p.Arg163Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000248 in 1,613,862 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R163S) has been classified as Uncertain significance.
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:2
Uncertain significance, criteria provided, single submitter
clinical testing
Mendelics
May 28, 2019
- -
Uncertain significance, criteria provided, single submitter
clinical testing
All of Us Research Program, National Institutes of Health
Aug 28, 2023
This missense variant replaces arginine with threonine at codon 163 of the BRCA1 protein. Computational prediction tools and conservation analyses are inconclusive regarding the impact of this variant on the protein function. Computational splicing tools suggest that this variant may not impact RNA splicing. To our knowledge, functional assays have not been performed for this variant. This variant has been observed in two individuals who underwent BRCA mutation testing in cohorts with personal or family history of BRCA-associated cancers (PMID: 29020660, 30675319). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Aug 15, 2020
- -
Uncertain significance, criteria provided, single submitter
clinical testing
GeneDx
Feb 05, 2024
Observed in individuals with personal and/or family history of breast and/or ovarian cancer (PMID: 29020660, 30675319, 36329109); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as 607G>C; This variant is associated with the following publications: (PMID: 32438681, 30675319, 29884841, 32377563, 29020660, 36329109, 35150867, 20215511) -
Uncertain significance, criteria provided, single submitter
clinical testing
Ambry Genetics
Feb 10, 2023
The p.R163T variant (also known as c.488G>C), located in coding exon 6 of the BRCA1 gene, results from a G to C substitution at nucleotide position 488. The arginine at codon 163 is replaced by threonine, an amino acid with similar properties. This alteration has been identified in multiple individuals with a personal and/or family history of breast and/or ovarian cancer (Santonocito C et al. Breast, 2017 Dec;36:74-78; Farra C et al. Hered Cancer Clin Pract, 2019 Jan;17:4; Santonocito C et al. Cancers (Basel), 2020 May;12:; Matta BP et al. Sci Rep, 2022 Nov;12:18629). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Uncertain significance, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Aug 21, 2023
This missense variant replaces arginine with threonine at codon 163 of the BRCA1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in two individuals affected with breast and/or ovarian cancer (PMID: 32438681, 36329109) and in a suspected hereditary breast and ovarian cancer family (PMID: 30675319). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary breast ovarian cancer syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter
clinical testing
Labcorp Genetics (formerly Invitae), Labcorp
Jan 21, 2024
This sequence change replaces arginine, which is basic and polar, with threonine, which is neutral and polar, at codon 163 of the BRCA1 protein (p.Arg163Thr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with a personal and/or family history of breast and/or ovarian cancer (PMID: 29020660, 30675319, 32438681, 36329109). ClinVar contains an entry for this variant (Variation ID: 531359). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA1 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submitter
research
Genetics Program, Instituto Nacional de Cancer
Nov 01, 2021
- -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Oct 20, 2017
Variant summary: The BRCA1 c.488G>C (p.Arg163Thr) variant involves the alteration of a non-conserved nucleotide. 3/5 in silico tools predict a benign outcome for this variant, however the impact of this change on protein function is yet to be studied. This variant is absent in 277220 control chromosomes. The variant of interest has been reported in at least one unaffected individual from HBCO family without strong evidence for causality (Santonocito_2017). Due to insufficient evidence, the variant is classified as a variant of uncertain significance (VUS) until additional information becomes available. -